Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Noosa News23 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News23 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
General21 hours agoDairy farmers devastated by floods across parts of New South Wales
-
General24 hours ago‘Aussie Cossack’ Simeon Boikov’s legal fees paid by fund linked to Russian intelligence